New data on haematopoetic stem cell transplantation using treosulfan-based conditioning regimen

Wedel, Germany (18.3.2021) At this year’s medac symposium “Current Developments in Allogeneic Haematopoietic Stem Cell Transplantation: Recent Data on Treosulfan” on the occasion of the Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)1 five internationally renowned key opinion leaders presented the most recent data and developments in reduced-toxicity conditioning (RTC) with treosulfan (Trecondi®) prior to allogeneic haematopoietic stem cell transplantation (HSCT).

Click here for more information